Navigation Links
BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
Date:11/3/2008

NOVATO, Calif, Nov. 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today the initiation of the Morquio Clinical Assessment Program (MorCAP) for patients with the lysosomal storage disease Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. MorCAP is designed to augment available data on the disease by measuring endurance and respiratory function and other parameters in affected patients. BioMarin expects to follow the MorCAP program with a Phase 1b clinical trial of enzyme replacement therapy beginning in the first quarter of 2009. The primary objectives of the Phase 1b study will be to evaluate safety and to establish the optimal dose of enzyme based on pharmacokinetic and pharmacodynamic parameters.

"After successfully advancing two enzyme replacement therapies in approximately five years each from IND filing to FDA approval, we plan to leverage our clinical, manufacturing and regulatory expertise to develop a treatment for Morquio A syndrome," said Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin. "Preliminary studies are promising and indicate that our drug candidate binds naturally to bone matrix and can adequately reach the growth cartilage after IV infusion. We recently have also shown that GALNS can reduce keratan sulfate storage in Morquio chondrocytes. This is important as the skeletal system is a primary concern in the treatment of this disease."

"We are excited to be the first site to enroll patients in the BioMarin Clinical Assessment Program for MPS IVA patients. This study is crucial to developing a deeper understanding of the clinical outcomes for this rare disorder, which will help lead to better disease management and therapy options, said Barbara B
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... York, New York (PRWEB) May 05, 2015 ... lawsuits ( http://www.testosteronelawsuithub.com/ ) filed on behalf ... complications due to their use of prescription ... in the federal multidistrict litigation underway in ... According to court documents dated May 1st, ...
(Date:5/5/2015)... May 05, 2015 From the ... the established leader in enabling enterprise collaboration across ... help customers speed up and simplify the move ... AvePoint Solutions for Office 365 enable ... while ensuring sustainable user adoption and effectively managing ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Viverae®, ... C.R. Bard Inc., a leading multinational developer, manufacturer ... the fields of vascular, urology, oncology and surgical ... Vanguard Award. The Vanguard Award recognizes outstanding ... wellness programs among Viverae’s significant client base. , ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 The newly ... on the experiences of Dr. Brad Reedy from his ... Judith Regan was asked why she chose to publish a parenting ... as a parent (and publisher) is the idea that it is ... we and our children are on the trek sometimes together and ...
(Date:5/5/2015)... 2015 Baptist Medical Center Jacksonville’s cancer ... (CoC) of the American College of Surgeons. , To ... more than 30 Commission on Cancer quality care standards, ... and maintain levels of excellence in the delivery of ... to seek care locally at a CoC-accredited cancer center, ...
Breaking Medicine News(10 mins):Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 2Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 3Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4
... research facility in Toronto in Ontario Institute for Cancer ... The new research facility will act as a network ... will consist of // researchers from various Universities ... a team in providing new treatment methods for cancer. ...
... patients with whooping cough/Pertussis have tripled in Idaho (central) and ... infectious respiratory disease. 72 cases have been ... in Ada (55 cases), Boise, Elmore (17) and Valley counties ... are on the rise when compared to the 10 year ...
... published in the December issue of Arthritis and Rheumatism says ... a vital role in the pathogenesis of rheumatoid arthritis (RA), ... protein was found by a team of researchers at the ... of London. It appears that the protein modifies itself and ...
... Researchers at the Virginia Commonwealth University have found that ... periodontitis may be responsible for increasing the risk of ... ,Periodontitis is the inflammation of the supporting tissue that ... presence with a host of diseases including diabetes and ...
... has spread its wings over the Crimean peninsula. The cases have ... in the government as well as public. // ,To ... to determine if the virus is the deadly strain that has ... has been called for by the Ukrainian president in some parts ...
... health sector of England has both doctors and nurses of ... almost 20 percent.// The National Health Service (NHS) of ... Children's Hospital, in the Wellchild awards. ,Jaswant ... has been honoured in a national competition. Children's health charity ...
Cached Medicine News:Health News:Severe Gum Disease Triples Heart Disease Risk 2
(Date:5/5/2015)... -- The Association of periOperative Registered Nurses (AORN) has awarded ... Stop and Go Sign designed by Christopher ... M.D., anesthesia providers with Anaesthesia Associates of Massachusetts ... is distributed by the Plexus Management Group, Inc. ... compliance with the AORN Safe Surgery Checklist. ...
(Date:5/5/2015)... , May 5, 2015 Merrimack Pharmaceuticals, ... of a randomized, double-blinded, placebo-controlled Phase 2 clinical ... and ErbB3, in combination with nab-paclitaxel and gemcitabine, ... newly-diagnosed metastatic pancreatic cancer who have high serum ... is the fourth leading cause of cancer death ...
(Date:5/5/2015)... May 5, 2015   Cynosure, Inc. (Nasdaq: ... devices for aesthetic procedures and precision surgical applications worldwide, ... March 31, 2015. First-Quarter Highlights: , ... , Non-GAAP earnings of $0.15 per share; GAAP earnings ... at March 31, 2015 "Cynosure delivered 21 ...
Breaking Medicine Technology:The Preoperative Stop and Go Sign Interactive Checklist Awarded AORN Seal of Recognition 2The Preoperative Stop and Go Sign Interactive Checklist Awarded AORN Seal of Recognition 3Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 2Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 3Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 2Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 3Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 5Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 6Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 7Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 8Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 9Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 10Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 11
... today-, SAN CARLOS, Calif., March 17 Nuvelo, ... the Phase 2 program in,catheter occlusion (CO), known as ... Alfimeprase), did not,show sufficient improvement in catheter opening at ... meet the desired target product,profile. As a result, Nuvelo ...
... Findings, BEDMINSTER, N.J., March 17 NPS,Pharmaceuticals, ... top-line,results from a 28-week blinded Phase 3-extension study ... who are dependent,upon parenteral nutrition (PN). The extension ... had completed a 24-week randomized Phase 3 study ...
Cached Medicine Technology:Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 2Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 3Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 4NPS Reports Successful GATTEX(TM) Extension Study 2NPS Reports Successful GATTEX(TM) Extension Study 3NPS Reports Successful GATTEX(TM) Extension Study 4NPS Reports Successful GATTEX(TM) Extension Study 5
... MIRAX SCAN is the system solution for digital ... monitor, a dual processor PC and software modules. ... scanner, which makes the specimens available as Digital ... quality, with the same optical resolution as on ...
... 1400 Series Biosafety Cabinets ... revolutionize working in a ... most comfortable, quiet, and ... cabinet on the market, ...
... Designed for ease of use and patient ... smooth edges for comfort and is available ... to a perfect fit. For hard to ... trach collar to your specifications. Don't just ...
Velcro® Tracheostomy tube holders are available in Adult, pediatric, and infant sizes....
Medicine Products: